Cargando…
Dihydroorotate dehydrogenase Inhibitors Target c-Myc and Arrest Melanoma, Myeloma and Lymphoma cells at S-phase
Dihydroorotate dehydrogenase (DHODH) is a rate-limiting enzyme in the de novo biosynthesis pathway of pyrimidines. Inhibition of this enzyme impedes cancer cell proliferation but the exact mechanisms of action of these inhibitors in cancer cells are poorly understood. In this study, we showed that c...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604460/ https://www.ncbi.nlm.nih.gov/pubmed/28928900 http://dx.doi.org/10.7150/jca.14835 |
_version_ | 1783264871658291200 |
---|---|
author | Dorasamy, Mathura Subangari Choudhary, Bhavesh Nellore, Kavitha Subramanya, Hosahalli Wong, Pooi-Fong |
author_facet | Dorasamy, Mathura Subangari Choudhary, Bhavesh Nellore, Kavitha Subramanya, Hosahalli Wong, Pooi-Fong |
author_sort | Dorasamy, Mathura Subangari |
collection | PubMed |
description | Dihydroorotate dehydrogenase (DHODH) is a rate-limiting enzyme in the de novo biosynthesis pathway of pyrimidines. Inhibition of this enzyme impedes cancer cell proliferation but the exact mechanisms of action of these inhibitors in cancer cells are poorly understood. In this study, we showed that cancer cells, namely melanoma, myeloma and lymphoma overexpressed DHODH protein and treatment with A771726 and Brequinar sodium resulted in cell cycle arrest at S-phase. Transfection with DHODH shRNA depleted DHODH protein expression and impeded the proliferation of melanoma cells. shRNA knockdown of DHODH in combination with DHODH inhibitors further reduced the cancer cell proliferation, suggesting that knockdown of DHODH had sensitized the cells to DHODH inhibitors. Cell cycle regulatory proteins, c-Myc and its transcriptional target, p21 were found down- and up-regulated, respectively, following treatment with DHODH inhibitors in melanoma, myeloma and lymphoma cells. Interestingly, knockdown of DHODH by shRNA had also similarly affected the expression of c-Myc and p21 proteins. Our findings suggest that DHODH inhibitors induce cell cycle arrest in cancer cells via additional DHODH-independent pathway that is associated with p21 up-regulation and c-Myc down-regulation. Hence, DHODH inhibitors can be explored as potential therapeutic agents in cancer therapy. |
format | Online Article Text |
id | pubmed-5604460 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-56044602017-09-19 Dihydroorotate dehydrogenase Inhibitors Target c-Myc and Arrest Melanoma, Myeloma and Lymphoma cells at S-phase Dorasamy, Mathura Subangari Choudhary, Bhavesh Nellore, Kavitha Subramanya, Hosahalli Wong, Pooi-Fong J Cancer Research Paper Dihydroorotate dehydrogenase (DHODH) is a rate-limiting enzyme in the de novo biosynthesis pathway of pyrimidines. Inhibition of this enzyme impedes cancer cell proliferation but the exact mechanisms of action of these inhibitors in cancer cells are poorly understood. In this study, we showed that cancer cells, namely melanoma, myeloma and lymphoma overexpressed DHODH protein and treatment with A771726 and Brequinar sodium resulted in cell cycle arrest at S-phase. Transfection with DHODH shRNA depleted DHODH protein expression and impeded the proliferation of melanoma cells. shRNA knockdown of DHODH in combination with DHODH inhibitors further reduced the cancer cell proliferation, suggesting that knockdown of DHODH had sensitized the cells to DHODH inhibitors. Cell cycle regulatory proteins, c-Myc and its transcriptional target, p21 were found down- and up-regulated, respectively, following treatment with DHODH inhibitors in melanoma, myeloma and lymphoma cells. Interestingly, knockdown of DHODH by shRNA had also similarly affected the expression of c-Myc and p21 proteins. Our findings suggest that DHODH inhibitors induce cell cycle arrest in cancer cells via additional DHODH-independent pathway that is associated with p21 up-regulation and c-Myc down-regulation. Hence, DHODH inhibitors can be explored as potential therapeutic agents in cancer therapy. Ivyspring International Publisher 2017-09-05 /pmc/articles/PMC5604460/ /pubmed/28928900 http://dx.doi.org/10.7150/jca.14835 Text en © Ivyspring International Publisher This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions. |
spellingShingle | Research Paper Dorasamy, Mathura Subangari Choudhary, Bhavesh Nellore, Kavitha Subramanya, Hosahalli Wong, Pooi-Fong Dihydroorotate dehydrogenase Inhibitors Target c-Myc and Arrest Melanoma, Myeloma and Lymphoma cells at S-phase |
title | Dihydroorotate dehydrogenase Inhibitors Target c-Myc and Arrest Melanoma, Myeloma and Lymphoma cells at S-phase |
title_full | Dihydroorotate dehydrogenase Inhibitors Target c-Myc and Arrest Melanoma, Myeloma and Lymphoma cells at S-phase |
title_fullStr | Dihydroorotate dehydrogenase Inhibitors Target c-Myc and Arrest Melanoma, Myeloma and Lymphoma cells at S-phase |
title_full_unstemmed | Dihydroorotate dehydrogenase Inhibitors Target c-Myc and Arrest Melanoma, Myeloma and Lymphoma cells at S-phase |
title_short | Dihydroorotate dehydrogenase Inhibitors Target c-Myc and Arrest Melanoma, Myeloma and Lymphoma cells at S-phase |
title_sort | dihydroorotate dehydrogenase inhibitors target c-myc and arrest melanoma, myeloma and lymphoma cells at s-phase |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604460/ https://www.ncbi.nlm.nih.gov/pubmed/28928900 http://dx.doi.org/10.7150/jca.14835 |
work_keys_str_mv | AT dorasamymathurasubangari dihydroorotatedehydrogenaseinhibitorstargetcmycandarrestmelanomamyelomaandlymphomacellsatsphase AT choudharybhavesh dihydroorotatedehydrogenaseinhibitorstargetcmycandarrestmelanomamyelomaandlymphomacellsatsphase AT nellorekavitha dihydroorotatedehydrogenaseinhibitorstargetcmycandarrestmelanomamyelomaandlymphomacellsatsphase AT subramanyahosahalli dihydroorotatedehydrogenaseinhibitorstargetcmycandarrestmelanomamyelomaandlymphomacellsatsphase AT wongpooifong dihydroorotatedehydrogenaseinhibitorstargetcmycandarrestmelanomamyelomaandlymphomacellsatsphase |